Brainstorm Cell Therapeut... (BCLI)
0.75
-0.01 (-1.63%)
At close: Apr 14, 2025, 12:52 PM
-1.63% (1D)
| Bid | 0.75 |
| Market Cap | 4.9M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -11.62M |
| EPS (ttm) | -2.31 |
| PE Ratio (ttm) | -0.33 |
| Forward PE | -1.26 |
| Analyst | Buy |
| Ask | 0.78 |
| Volume | 52,261 |
| Avg. Volume (20D) | 142,754 |
| Open | 0.75 |
| Previous Close | 0.76 |
| Day's Range | 0.75 - 0.79 |
| 52-Week Range | 0.75 - 10.05 |
| Beta | 0.59 |
About BCLI
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative ...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 7, 2003
Employees 27
Stock Exchange NASDAQ
Ticker Symbol BCLI
Website https://www.brainstorm-cell.com
Analyst Forecast
According to 1 analyst ratings, the average rating for BCLI stock is "Buy." The 12-month stock price forecast is $30, which is an increase of 3892.55% from the latest price.
Stock Forecasts5 months ago
+1.67%
Brainstorm Cell Therapeutics and Pluri shares are ...
Unlock content with
Pro Subscription
6 months ago
-0.86%
Brainstorm Cell Therapeutics shares are trading higher after the company announced its CEO will discuss its Phase 3b ALS trial at the Maxim Healthcare virtual summit.
